GlassScriptPhysician profile
Jessica Mcclard
NPI 1790277556
$16,154.88
in general payments reported to CMS, 2019-2025
43 companies · $981 in 2025
The $981 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $157 · 2020: $97.99 · 2021: $467 · 2022: $12K · 2023: $1,382 · 2024: $972 · 2025: $981.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,336.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,336.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $10,000.00 | 2022 | |
| Abbvie INC. | $953.05 | 2022-2025 | |
| Amneal Pharmaceuticals LLC | $903.89 | 2022-2025 | Crexont |
| Teva Pharmaceuticals USA, INC. | $659.35 | 2022-2025 | Austedo Xr, Austedo Xr, Austedo |
| Neurocrine Biosciences, INC. | $302.06 | 2022-2025 | Ingrezza, Ongentys |
| Mdd US Operations, LLC | $243.20 | 2023-2025 | Gocovri, Gocovri, Myobloc |
| Greenwich Biosciences, INC. | $240.87 | 2019-2021 | |
| Sk Life Science, INC. | $224.01 | 2021-2024 | |
| Pfizer INC. | $217.09 | 2019-2025 | |
| Ucb, INC. | $201.35 | 2022-2025 | Briviact |
| Alexion Pharmaceuticals, INC. | $200.38 | 2021-2023 | Ultomiris, Soliris |
| Supernus Pharmaceuticals, INC. | $189.45 | 2022-2025 | Qelbree |
| Abbott Laboratories | $135.50 | 2022 | |
| Acadia Pharmaceuticals INC | $126.96 | 2022-2025 | Nuplazid |
| Acorda Therapeutics, INC | $107.84 | 2022-2024 | Inbrija |
Show all 43 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurelis, INC. | $107.25 | 2021-2024 | Valtoco |
| Avion Pharmaceuticals | $98.60 | 2022-2023 | Dhivy |
| Argenx US, INC. | $96.99 | 2022-2025 | Vyvgart, Vyvgart Hytrulo |
| Tanabe Pharma America, INC. | $90.70 | 2022-2023 | |
| Kyowa Kirin, INC. | $86.14 | 2022-2024 | Nourianz |
| Sunovion Pharmaceuticals INC. | $85.30 | 2021-2022 | |
| Lilly USA, LLC | $85.21 | 2024-2025 | Amyvid, Kisunla |
| Amylyx Pharmaceuticals, INC. | $80.76 | 2023 | Relyvrio |
| Merz Pharmaceuticals, LLC | $76.81 | 2022-2025 | Xeomin, Inbrija |
| Allergan, INC. | $72.88 | 2020-2021 | |
| Jazz Pharmaceuticals INC. | $68.06 | 2022-2023 | |
| Eisai INC. | $58.66 | 2022-2023 | |
| Livanova USA, INC. | $54.93 | 2020-2022 | |
| Biogen, INC. | $46.45 | 2025 | Skyclarys |
| Biohaven Pharmaceutical Holding Company LTD. | $40.25 | 2022 | |
| Ipsen Biopharmaceuticals, INC | $36.78 | 2022-2023 | Dysport |
| Nevro Corp. | $35.20 | 2021 | |
| Genzyme Corporation | $31.43 | 2019-2021 | |
| Portola Pharmaceuticals, LLC | $25.45 | 2019 | |
| Vanda Pharmaceuticals INC. | $24.98 | 2025 | Ponvory |
| Otsuka America Pharmaceutical, INC. | $22.73 | 2023 | Rexulti |
| Biohaven Pharmaceuticals, INC. | $21.05 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $20.12 | 2022 | |
| Amgen INC. | $19.60 | 2020 | |
| Zogenix INC. | $19.34 | 2021 | |
| Upsher-Smith Laboratories LLC | $16.70 | 2019 | |
| Chiesi USA, INC. | $13.76 | 2025 | Cleviprex |
| Octapharma USA, INC. | $13.75 | 2024 | Panzyga |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jessica Mcclard listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.